ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding ARS Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 73 | 90 | +17 |
| Shares | 50.2M | 53.4M | +3.26M (+6.5%) |
| Value | $427.9M | $347.7M | −$80.1M (−18.7%) |
New holders (26)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (9)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Oasis Management Co Ltd. | 317,662 | $2.71M |
| EAM Global Investors LLC | 183,452 | $1.56M |
| New York Life Investment Management LLC | 161,617 | $1.38M |
| Algert Global LLC | 19,920 | $169.9K |
| Raymond James Financial Services Advisors, Inc. | 16,742 | $142.8K |
| Balyasny Asset Management LLC | 11,328 | $96.6K |
| Mirabella Financial Services LLP | 10,573 | $90.2K |
| Cannell Capital LLC | 9,402 | $80.2K |
| Advisor Group Holdings, Inc. | 2,000 | $17.0K |